| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11529368 | SALIX | Colonoscopy—preparation |
Mar, 2032
(7 years from now) | |
| US10780112 | SALIX | Colonoscopy-preparation |
Mar, 2032
(7 years from now) | |
| US10792306 | SALIX | Colonoscopy—preparation |
Mar, 2032
(7 years from now) | |
| US10646512 | SALIX | Colonoscopy - preparation |
Mar, 2032
(7 years from now) | |
| US9592252 | SALIX | Colonoscopy—preparation |
Aug, 2032
(8 years from now) | |
| US10918723 | SALIX | Colon cleansing compositions and methods of use |
Sep, 2033
(9 years from now) | |
| US8999313 | SALIX | Compositions |
Sep, 2033
(9 years from now) | |
| US9326969 | SALIX | Compositions |
Sep, 2033
(9 years from now) | |
| US9707297 | SALIX | Compositions |
Sep, 2033
(9 years from now) | |
| US10016504 | SALIX | Compositions |
Sep, 2033
(9 years from now) | |
Plenvu is owned by Salix.
Plenvu contains Ascorbic Acid; Polyethylene Glycol 3350; Potassium Chloride; Sodium Ascorbate; Sodium Chloride; Sodium Sulfate.
Plenvu has a total of 10 drug patents out of which 0 drug patents have expired.
Plenvu was authorised for market use on 04 May, 2018.
Plenvu is available in for solution;oral dosage forms.
Plenvu can be used as for cleansing of the colon in preparation for colonoscopy in adults.
The generics of Plenvu are possible to be released after 10 September, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 04, 2021 |
Market Authorisation Date: 04 May, 2018
Treatment: For cleansing of the colon in preparation for colonoscopy in adults
Dosage: FOR SOLUTION;ORAL
PLENVU family patents
